Authorized HIV PrEP/PEP Medications

Business and Professions Code (BPC) section 4052.02 authorizes pharmacists to initiate and furnish HIV preexposure prophylaxis (PrEP). BPC section 4052.03 authorizes pharmacists to initiate and furnish HIV postexposure prophylaxis (PEP).

BPC section 4052.02(b) defines PrEP as a fixed-dose combination of tenofovir disoproxil fumarate (TDF) (300 mg) with emtricitabine (FTC) (200 mg), or another drug or drug combination determined by the board to meet the same clinical eligibility recommendations provided in CDC Guidelines.

BPC section 4052.03(b) defines PEP as:

(1) Tenofovir disoproxil fumarate (TDF) (300 mg) with emtricitabine (FTC) (200 mg), taken once daily, in combination with either raltegravir (400 mg), taken twice daily, or dolutegravir (50 mg), taken once daily.
(2) Tenofovir disoproxil fumarate (TDF) (300 mg) and emtricitabine (FTC) (200 mg), taken once daily, in combination with darunavir (800 mg) and ritonavir (100 mg), taken once daily.
(3) Another drug or drug combination determined by the board to meet the same clinical eligibility recommendations provided in CDC guidelines.

On September 17, 2020, the Board of Pharmacy approved the following additional drug combinations:

• A fixed-dose combination of tenofovir alafenamide (TAF) (25 mg) with emtricitabine (FTC) (200 mg) as a drug combination that can be initiated and furnished for preexposure prophylaxis (PrEP) by a pharmacist pursuant to the provisions of BPC 4052.02.
• Approve bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide/25mg as a drug combination that can be initiated and furnished for postexposure prophylaxis (PEP) by a pharmacist pursuant to the provisions of BPC 4052.03.